DUPILUMAB IMPROVES HISTOLOGIC AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS IN CHILDREN AGED 1-11 YEARS IN THE PHASE 3 EOE KIDS TRIAL

被引：0
|
作者：
Chehade, Mirna
Dellon, Evan S.
Spergel, Jonathan
Rothenberg, Marc E.
Liu, Ruiqi
Mannent, Leda
Laws, Elizabeth
Mortensen, Eric
Maloney, Jennifer
Khokhar, Faisel
Beazley, Bethany
Glotfelty, Lila
Shabbir, Arsalan
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
605
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 48 条
  • [21] Parent-assessed EoE activity in children aged 3-9 years does not correlate with physician global assessment, endoscopic and histologic activity
    Safroneeva, Ekaterina
    Coslovsky, Micheal
    Panczak, Radek
    Kuehni, Claudia
    Wahlen, Marcel Z.
    Trelle, Sven
    Limacher, Andreas
    Haas, Nadine
    Straumann, Alex
    Schoepfer, Alain
    SWISS MEDICAL WEEKLY, 2015, 145 : S8 - S8
  • [22] ENDOSCOPIC FEATURES ARE SIGNIFICANTLY ASSOCIATED WITH HISTOLOGIC MEASURES OF DISEASE ACTIVITY IN PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS: A POST HOC ANALYSIS OF A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 DUPILUMAB TRIAL
    Hirano, Ikuo
    Collins, Margaret H.
    Dellon, Evan S.
    Rothenberg, Marc E.
    Schoepfer, Alain M.
    Chehade, Mirna
    Chen, Zhen
    Mannent, Leda
    Graham, Neil M.
    Pirozzi, Gianluca
    Hamilton, Jennifer D.
    Radin, Allen
    GASTROENTEROLOGY, 2018, 154 (06) : S243 - S244
  • [23] Dupilumab in children aged ≥6 to <12 years significantly improves severe atopic dermatitis: results from phase 3 trial (LIBERTY AD PEDS)
    Gooderham, M.
    Boguniewicz, M.
    Sher, L.
    Weisman, J.
    Bansal, A.
    Staudinger, H. W.
    Worrell, R.
    Patel, N.
    Graham, N. M. H.
    Ruddy, M.
    Sun, X.
    Beazley, B.
    Shumel, B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 59 - 60
  • [24] Determination of the Eosinophilic Esophagitis Endoscopic Reference Score Associated With Histologic Response to Therapy: Analysis From a Phase 3 Placebo-Controlled Trial of Budesonide Oral Suspension
    Hirano, Ikuo
    Collins, Margaret H.
    Katzka, David A.
    Mukkada, Vincent A.
    Falk, Gary W.
    Williams, James E.
    Desai, Nirav K.
    Lan, Lan
    Dellon, Evan S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S217 - S218
  • [25] Budesonide Oral Suspension Improves Histologic Features In Patients With Eosinophilic Esophagitis: Results From A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial
    Collins, Margaret
    Hirano, Ikuo
    Katzka, David
    Cianferoni, Antonella
    Williams, James
    Desai, Nirav
    Lan, Lan
    Dellon, Evan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB166 - AB166
  • [26] RAPID IMPROVEMENT IN ITCH IN CHILDREN AGED 6-11 YEARS WITH SEVERE ATOPIC DERMATITIS TREATED WITH DUPILUMAB: ANALYSIS FROM THE LIBERTY AD PEDS PHASE 3 TRIAL
    Paller, Amy S.
    Park, Young L.
    Lee, Dong H.
    Ahn, Jiyoung
    Yosipovitch, Gil
    Chen, Zhen
    Lee, Joo H.
    Prescilla, Randy
    Rossi, Ana B.
    Delevry, Dimittri
    ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 61 - 61
  • [27] Dupilumab Improves Health-Related Quality of Life (HRQoL) and Reduces Symptom Burden in Patients with Eosinophilic Esophagitis (EoE): Results From Part A of a Randomized, Placebo-Controlled Three-Part Phase 3 Study
    Dellon, Evan
    Rothenberg, Marc
    Hirano, Ikuo
    Chehade, Mirna
    Bredenoord, Albert J.
    Spergel, Jonathan
    Zhao, Qiong
    Beazley, Bethany
    Guillemin, Isabelle
    Mannent, Leda
    Laws, Elizabeth
    Amin, Nikhil
    Shumel, Brad
    Maloney, Jennifer
    Kamat, Siddhesh
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB91 - AB91
  • [28] Dupilumab for atopic dermatitis in children aged ≥6 to <12 years in phase 3 LIBERTY AD PEDS trial: Analysis by baseline weight
    Paller, A. S.
    Siegfried, E. C.
    Beck, L. A.
    O'Malley, J. T.
    Shumel, B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : B9 - B9
  • [29] Rapid and sustained improvement in itch in children aged 6 11 years with severe atopic dermatitis (AD) treated with dupilumab: Analysis from the LIBERTY AD PEDS phase 3 trial
    Paller, Amy S.
    Siegfried, Elaine C.
    Yosipovitch, Gil
    Silverberg, Jonathan I.
    Wu, Jashin J.
    Chen, Zhen
    Prescilla, Randy
    Rossi, Ana B.
    Delevry, Dimittri
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB140 - AB140
  • [30] Rapid and sustained improvement in Itch in children aged 6-11 years with severe atopic dermatitis treated with dupilumab: Analysis from the LIBERTY AD PEDS phase 3 trial
    Paller, A. S.
    Weidinger, S.
    Yosipovitch, G.
    Silverberg, J., I
    Wu, J. J.
    Bastian, M.
    Chen, Z.
    Prescilla, R.
    Rossi, A. B.
    Delevry, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 97 - 97
12345